Advanced Search

Technical Analysis for IDXG - Interpace Diagnostics Group, Inc.

Grade Last Price % Change Price Change
grade C 6.31 -1.41% -0.09
IDXG closed down 1.41 percent on Wednesday, August 5, 2020, on 29 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
1 Watcher
Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical IDXG trend table...
Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
200 DMA Support Bullish -1.41%
Wide Bands Range Expansion -1.41%
Up 3 Days in a Row Strength -1.41%
Up 4 Days in a Row Strength -1.41%
Crossed Above 200 DMA Bullish 2.94%
Spinning Top Other 2.94%
Older EOD signals for IDXG ...
View Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators Basic chart:

Profile

PDI, Inc. provides outsourced commercial services to pharmaceutical, biotechnology, diagnostics, and healthcare companies in the United States. It operates in two segments, Commercial Services and Interpace Diagnostics. The Commercial Services segment offers outsourced sales teams that target healthcare providers, providing a range of complementary sales support services designed to achieve its customers' strategic and financial product objectives. This segment offers a range of personal and non-personal promotional options for the commercialization of their products throughout the product lifecycles, from development through maturity. It also provides other promotional services, including clinical educator, teledetailing, and full product commercialization services. This segment's services include product distribution, personal and non-personal product detailing, full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management. The Interpace Diagnostics segment focuses on developing and commercializing molecular diagnostic tests for physicians and patients with diagnostic options for detecting genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. This segment offers PancraGen, a diagnostic test designed for determining risk of malignancy in pancreatic cysts; and ThyGenX, a next-generation sequencing test designed to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules. It also has three diagnostic tests in late stage development that are designed to detect genetic alterations that are associated with gastrointestinal cancers; and one diagnostic test in late stage development that is designed to detect genetic alterations that are associated with endocrine cancers. PDI, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Biotechnology Cancer Healthcare Life Sciences Biology Supply Chain Management Healthcare Providers Medical Genetics Diagnostic Tests Qiagen Gastrointestinal Cancers

Is IDXG a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Jul 21 Interpace Announces Acceptance of Seminal Clinical Validation Study for Thyroid Assays
Jul 6 66 Biggest Movers From Thursday
Jun 26 Interpace Q1 revenue +53%, shares -7.5%
Jun 25 Interpace Biosciences, Inc. (IDXG) CEO Jack Stover on Q1 2020 Results - Earnings Call Transcript
Jun 25 Edited Transcript of IDXG earnings conference call or presentation 25-Jun-20 8:30pm GMT
Jun 25 Interpace Biosciences EPS misses by $1.07, beats on revenue
Jun 25 Interpace Biosciences Announces First Quarter 2020 Financial and Business Results
Jun 25 Earnings Scheduled For June 25, 2020
Jun 24 Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020
Apr 27 Interpace Biosciences Announces Contract with Lab Benefits Management Firm
See more IDXG news...

Indicators

Indicator Value
52 Week High 11.0
52 Week Low 3.8
Average Volume 411,183
200-Day Moving Average 6.09
50-Day Moving Average 5.43
20-Day Moving Average 5.68
10-Day Moving Average 5.99
Average True Range 0.65
ADX 37.94
+DI 32.62
-DI 10.32
Chandelier Exit (Long, 3 ATRs ) 6.38
Chandelier Exit (Short, 3 ATRs ) 6.45
Upper Bollinger Band 6.78
Lower Bollinger Band 4.58
Percent B (%b) 0.79
BandWidth 38.66
MACD Line 0.24
MACD Signal Line 0.19
MACD Histogram 0.051
Fundamentals Value
Market Cap 139.83 Million
Num Shares 22.2 Million
EPS -1.17
Price-to-Earnings (P/E) Ratio -5.39
Price-to-Sales 2.01
Price-to-Book 0.69
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.78
Resistance 3 (R3) 6.76 6.60 6.70
Resistance 2 (R2) 6.60 6.48 6.60 6.67
Resistance 1 (R1) 6.45 6.41 6.37 6.47 6.65
Pivot Point 6.29 6.29 6.25 6.29 6.29
Support 1 (S1) 6.14 6.17 6.06 6.16 5.97
Support 2 (S2) 5.98 6.10 5.98 5.95
Support 3 (S3) 5.83 5.98 5.92
Support 4 (S4) 5.85